CIC biomaGUNE, a research center in Spain, has developed innovative pulmonary surfactant nanoparticles that encapsulate antifibrotic drugs for the treatment of pulmonary fibrosis. This condition leads to scarring of lung tissue, making breathing difficult. The nanoparticles, which utilize a biomimetic approach, are designed to improve drug delivery directly to the lungs, enhancing therapeutic effects while minimizing side effects. In tests on mice, it was found that 90% of these nanoparticles remain in the lungs, significantly reducing the amount of drug that reaches the liver compared to conventional treatments. The study, published in *Advanced Healthcare Materials*, details a simplified synthesis method that utilizes microfluidics for precise control over particle size and stability. This advancement could pave the way for more effective inhaled therapies for lung diseases. Dr. Susana Carregal, the lead researcher, emphasized the importance of targeting diseased tissue to improve treatment outcomes. The research was conducted in collaboration with the Complutense University of Madrid, highlighting a significant step forward in the field of pulmonary medicine.